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Abstract 
An underlying goal of synthetic biology is to make the process of engineering biological 
systems easier and more reliable.  In support of this goal, we developed BioBrick 
assembly standard 10 to enable the construction of systems from standardized genetic 
parts.  The BioBrick standard underpins the distributed efforts by the synthetic biology 
research community to develop a collection of more than 6000 standard genetic parts 
available from the Registry of Standard Biological Parts.  Here, we describe the three 
antibiotic assembly (3A assembly) method for physical composition of BioBrick parts 
and provide step-by-step protocols.  The method relies on a combination of positive and 
negative selection to eliminate time- and labor-intensive steps such as column cleanup 
and agarose gel purification of DNA during part assembly. 
1. Introduction 
A fundamental goal of synthetic biology is to make the process of designing, building 
and testing biological systems easier and more reliable.  Drawing inspiration from other 
engineering fields, we have been working to develop methods that support the design and 
construction of multi-component, synthetic biological systems from standardized 
biological parts.  In 2002, Knight proposed and implemented the BioBrick standard for 
assembly of standard genetic parts (Knight, 2003).  Parts that have been refined to adhere 
to the BioBrick assembly standard are called BioBrick standard biological parts.  The key 
innovation of the BioBrick standard is that assembly of any two BioBrick parts yields a 
composite object that is itself a BioBrick part that can be further combined with any other 
BioBrick parts.  The idempotent nature of the BioBrick standard has helped to support 
the distributed development of a collection of over 6000 standard biological parts in the 
Registry of Standard Biological Parts (http://partsregistry.org).  Parts in the Registry are 
catalogued, describing and conveying units of biological function rather than simply 
arbitrary DNA sequences.  Participants in the international Genetically Engineered 
Machines competition (iGEM, http://igem.org) as well as many academic laboratories 
have made use of the BioBrick assembly standard in construction of genetic parts, 
devices and systems (Levskaya et al., 2005; Ajo-Franklin et al., 2007; Canton et al., 
2008; Haynes et al., 2008; Shetty et al., 2008; Du et al., 2009; Kelly et al., 2009; Tabor et 
al., 2009; Agapakis et al., 2010; Afonso et al., 2010; Grünberg et al., 2010; Huang et al., 
2010).  Several additional physical composition standards have been proposed that extend 
or build upon the BioBrick assembly standard (Phillips and Silver, 2006; Knight, 2008; 
Ellison et al., 2009; Grünberg et al., 2009; Peisajovich et al., 2009; Anderson et al., 
2010).  The BioBricks Foundation (BBF) now manages an open standards setting process 
for the synthetic biology community via the submission and publication of requests for 
comment (RFCs).  In accordance with BBF RFC 29, the BioBrick assembly standard is 
now referred to as BioBrick assembly standard 10 in the Registry of Standard Biological 
Parts and other assembly standards are similarly numbered (Shetty and Rettberg, 2009).  
For brevity, here we use the term BioBrick parts to refer to parts that adhere to BioBrick 
assembly standard 10.   
 
In addition to supporting the distributed development of a collection of standard 
biological parts, the BioBrick standard also enables the iterative and pairwise hierarchical 
assembly of genetic parts into systems containing many parts.  The standard prescribes 
specific sequences, termed the prefix and suffix sequences, that must flank the 5’ and 3’ 
ends of a genetic part, respectively (Figure 1A and 1B).  The prefix sequence encodes an 
EcoRI and XbaI restriction enzyme recognition site and the suffix sequence encodes a 
SpeI and PstI recognition site.  In addition, the standard prescribes that the sequence of 
the genetic part itself must not contain recognition sites for EcoRI, XbaI, SpeI or PstI 
enzymes.  During assembly of any two BioBrick parts, the 3’ end of the upstream part is 
digested with SpeI and the 5’ end of the downstream part is digested with XbaI.  Since 
SpeI and XbaI produce compatible cohesive ends, ligation of the upstream and 
downstream parts produces an 8 bp “mixed” or “scar” sequence between the two parts 
that is not recognized by either enzyme (Figure 1C).  Since the resulting composite part is 
still flanked by the prefix and suffix sequences, it can again be digested with either XbaI 
or SpeI during a subsequent assembly step.  Hence, a biological engineer can use the 
same, iterative process of restriction digestion and ligation to assemble multiple parts into 
a synthetic biological system. 
 
Although the BioBrick standard constrains the sequence of the genetic parts as well as the 
overall assembly approach, it does not specify the methods used during the assembly 
process.  As a result, there has been some variation and experimentation on assembly 
methods by different research groups (Knight, 2003; Sleight et al., 2010).  Here, we 
describe a method for assembly of BioBrick parts called three antibiotic assembly (3A 
assembly, Figure 2).  We designed the 3A assembly method to make use of negative and 
positive selection to reduce the number of possible incorrect assembly products.  The 
inputs to the process are plasmids propagating an upstream part, a downstream part, and a 
destination vector into which the two parts will be assembled.  The destination vector 
must have a different antibiotic resistance marker from the plasmids encoding the 
upstream and downstream parts.  (The name 3A assembly derives from the maximum of 
three antibiotic resistance markers needed for any assembly step.)  The upstream part is 
digested with EcoRI and SpeI, the downstream part is digested with XbaI and PstI and 
the destination vector is digested with EcoRI and PstI.  The three digested plasmids are 
then mixed, ligated and transformed with no intervening purification steps.  Given the 
variety of DNA fragments present in the ligation reaction, an assortment of ligation 
products are possible in 3A assembly (Figure 3).  Fortunately, transformation and 
subsequent colony growth on selective media constitute strong selective pressure for 
circular ligation products that include the destination vector.  In addition, propagation of 
the uncut or recircularized destination plasmid is selected against by inclusion of the 
ccdB positive selection marker in the BioBrick cloning site of the destination vector 
(Bernard et al., 1994; Bernard, 1995; Bernard, 1996).  Ligation products composed of 
part concatemers, though possible, occur with significantly lower probability than the 
desired ligation product.  Finally, ligation products with two or more identical replication 
origins usually fail to propagate in growing E. coli cells.  Hence, there is significant 
positive and negative selective pressure for the transformation and propagation of the 
desired assembly product.  As an additional benefit of the 3A assembly method, it is very 
amenable to scale up and automation because it avoids difficult-to-automate steps such as 
column cleanup and agarose gel purification of DNA.  We have successfully used the 
method to assemble parts ranging in length from 12 bp to 3-4 kb.  Below, we provide 
detailed protocols for the construction and 3A assembly of BioBrick parts.  All protocols 
are adapted from standard molecular biology techniques and/or the manufacturer’s 
directions, unless otherwise specified (Sambrook and Russell, 2001). 
2. Construction of new BioBrick standard biological parts 
To adhere to BioBrick assembly standard 10, genetic parts must be designed with specific 
prefix and suffix sequences (Figure 1A).  The suffix sequence for all BioBrick genetic 
parts is 5’ TACTAGTAGCGGCCGCTGCAG 3’.  The prefix sequence for genetic parts, with 
the exception of protein coding sequence parts, is 5’ GAATTCGCGGCCGCTTCTAGAG 3’.  
For protein coding sequences beginning with an ATG start codon, the prefix sequence is 
truncated by 2 nt at the 3’ end (Figure 1B).  The 2 nt truncation ensures that, when 
assembled together, two genetic parts encoding a ribosome binding site and a protein 
coding sequence have a suitable spacing between the Shine-Dalgarno sequence and the 
ATG start codon to promote efficient translation in E. coli and related organisms (Chen et 
al., 1994).  Hence, the prefix sequence for protein coding sequence parts beginning with 
an ATG start codon is 5’ GAATTCGCGGCCGCTTCTAG 3’.  An additional constraint on 
the sequence of parts conforming to BioBrick assembly standard 10 is that recognition 
sites for the following restriction enzymes must be absent: EcoRI, XbaI, SpeI, and PstI. 
 
New BioBrick parts can be constructed by either PCR amplification from template DNA 
or by de novo DNA synthesis.  For PCR-based construction of parts, we routinely use the 
primer sequences listed in Table I in which the prefix and suffix sequences are encoded 
on the forward and reverse primers, respectively.  Both the forward and reverse 
amplification primers are designed to have an extra 8 nt of sequence on the 5’ end.  The 8 
nt spacer sequence serves two purposes.  First, it enables efficient cleavage of the linear 
PCR product by EcoRI or PstI, as restriction enzymes cleave less efficiently near DNA 
termini (Moreira and Noren, 1995).  Second, the selected sequence GTTTCTT was found 
to promote the addition of a 3’ A overhang by Taq polymerase thereby facilitating 
downstream TA cloning of the PCR amplified part (Brownstein et al., 1996).  Optimal 
PCR conditions will vary based on part length, sequence, and amplification primers.  
When constructing a new part by PCR amplification, any EcoRI, XbaI, SpeI or PstI 
recognition sites present in the part sequence must be eliminated by site-directed 
mutagenesis.  For parts that are constructed by de novo DNA synthesis, we recommend 
eliminating the restriction sites listed in Table II when possible to facilitate conversion to 
other BioBrick assembly standards, part reuse and downstream cloning operations.  We 
also recommend cloning constructed parts into a standard BioBrick vector prior to 3A 
assembly. 
3. 3A assembly of BioBrick standard biological parts 
To assemble two BioBrick parts together into a destination vector via 3A assembly 
(Figure 2), we recommend the following protocol.  Enzymes and reagents are available 
from New England Biolabs, Ipswich, MA in the BioBrick Assembly Kit (Catalog # 
E0546S). 
 
1. Digest the upstream part with EcoRI-HF and SpeI, the downstream part with XbaI 
and PstI and the destination vector with EcoRI-HF and PstI.  The destination 
vector must have a different antibiotic resistance marker from both the upstream 
and downstream part.  Prepare all three digestion reactions with 500 ng plasmid 
DNA, 1X NEBuffer 2, 100 µg/ml Bovine Serum Albumin and 1 µL each enzyme 
in a total volume of 50 µL.  Note that issues in the digest step arise if nearly all of 
the reaction volume consists of plasmid DNA from miniprep.  Residual ethanol 
and/or guanidine hydrochloride contamination in miniprep eluant is common and 
can inhibit subsequent digestion.  A significant volume of the digest reaction 
volume should consist of water to dilute these impurities. 
2. Incubate all three reactions at 37°C for 15 minutes to digest the DNA and then at 
80°C for 20 minutes to heat inactivate the restriction enzymes.  For convenience, 
we recommend performing this step in a programmable thermocycler.  If 
troubleshooting, confirm digestion by analyzing 20 µL of reaction by agarose gel 
electrophoresis.  
3. Prepare the ligation reaction with 2 µL from each digest reaction, 1X T4 DNA 
ligase reaction buffer, and 1 µL T4 DNA ligase in a total volume of 20 µL.  It is 
not necessary to purify the linearized part DNA prior to ligation.  Ligation 
reactions are done at low DNA concentrations to favor production of circular 
DNA rather than concatemers.  Quick ligation buffers are not desirable for the 
cohesive end ligations used here. 
4. Incubate the ligation reaction at room temperature for 10 minutes.  Store the 
ligation reaction at -20°C or proceed immediately to the chemical transformation 
step.  We prefer chemical transformation to electroporation because it is easier to 
do a large numbers of transformations in parallel. 
5. Thaw the chemically competent cells on ice.  Competent cells can be purchased 
commercially (e.g., NEB 10-beta competent E. coli (High Efficiency)) or can be 
prepared via the protocol below.  Regardless, it is important to verify 
experimentally that the competent cells used have a high transformation 
efficiency (>108 cfu per µg of plasmid DNA is desirable). 
6. Prepare a transformation reaction by adding 1 µL of ligation reaction to 15-50 µL 
competent cells in a pre-chilled 2 mL eppendorf tube.  Increasing the amount of 
ligation product in the transformation reaction is usually not effective in 
increasing the number of transformants.  Less than 5% of the transformation 
reaction volume should consist of ligation product.  A 2 ml rather than a 1.7 ml 
eppendorf tube provides better mixing and aeration of the cell culture during 
outgrowth in a rotator (Step 11). 
7. Incubate the transformation reaction on ice for 30 minutes. 
8. Immerse the transformation reaction in a 42°C water bath for 60 seconds to heat 
shock the cells. 
9. Incubate the transformation reaction on ice for 2 minutes. 
10. Add 200 µL sterile SOC media to the transformation reaction to begin cell 
outgrowth. 
11. Incubate the transformation reaction at 37°C for 2 hours with gentle shaking.  
Although a 1 hour incubation is sufficient for destination vectors with ampicillin 
or kanamycin resistance markers, we have found that a 2 hour incubation results 
in an increased number of colonies for destination vectors with chloramphenicol 
or tetracycline markers. 
12. Using sterile 3 mm glass beads, spread 200 µL of the transformation reaction on 
an LB agar plate supplemented with the antibiotic corresponding to the 
destination vector.  Sterile glass beads are preferable to a glass spreader because 
multiple transformation reactions can be plated simultaneously. 
13. Incubate transformation plates overnight at 37°C for colony growth. 
 An attractive, automation-friendly alternative to plating the transformation reaction on 
LB agar plates is to perform serial dilution of the outgrowth cultures.  Outgrowth can be 
done in the first, leftmost column of a 96 deep-well plate in which each well is filled with 
316 µL of SOC medium.  Fill remaining wells with 684 µL of LB medium supplemented 
with the appropriate antibiotic and 0.002% cresol red.  Serial dilutions, transferring 316 
µL each time, result in 10X dilutions every two columns.  Incubate plates overnight at 
37°C for cell growth.  A red to yellow color change in a well indicates cell growth.  Pick 
the last, rightmost (most dilute) yellow well and test for correct assembly as described 
below.  This approach is only viable given the high likelihood and strong selection for 
correctly assembled parts in 3A assembly. 
4. Verification of correct assembly of BioBrick standard biological parts 
Based on our empirical observations, 3A assembly usually yields more than 80% correct 
clones, assuming that the assembled parts confer no significant growth disadvantage to 
the host strain.  To confirm that two parts have been correctly assembled together via 3A 
assembly, we routinely screen colonies for sensitivity to the antibiotic(s) corresponding to 
the two part vectors and verify the length of the assembled part by colony PCR followed 
by agarose gel elecrophoresis as described below (Güssow and Clackson, 1989).  Clones 
that pass these two checks are then analyzed by DNA sequencing.   
1. Use a sterile tip to pick, inoculate and mix a colony into 20 µL of sterile H2O.  
We generally pick 4 or 8 colonies from each transformation plate.  For this and all 
subsequent steps, we use 8-strip PCR tubes and/or 96-well plates to facilitate use 
of a multi-channel pipettor for the transfer operations. 
2. Transfer ~2 µL of the colony suspension onto four LB-agar plates each 
supplemented with one of ampicillin, kanamycin, chloramphenicol and 
tetracycline. Incubate the plates either at room temperature overnight or at 37°C 
for 6-8 hours to check for the expected antibiotic resistance and sensitivity. 
3. For each colony suspension, prepare 9.5 µL PCR mix using primers BioBricks-f 
and BioBricks-r that anneal to the BioBrick prefix and suffix, respectively (Table 
I).  Transfer 0.5 µL colony suspension to each reaction tube and run PCR in a 
programmable thermocycler.  Optimal PCR conditions will vary based on part 
length and sequence but generally an annealing temperature of 56-58°C works 
well with these primers.  We prefer to use colony verification primers BioBricks-f 
and BioBricks-r rather than sequencing primers VF2 and VR in this step to test 
for the presence of a BioBrick prefix and suffix in the assembled clones. 
4. Analyze the resulting reactions by agarose gel electrophoresis.  Confirm that the 
PCR product has the expected length by comparison to a molecular weight 
standard (DNA ladder). 
5. Sequence plasmid DNA from 1-2 colonies per assembly from those colonies that 
pass both the antibiotic resistance/sensitivity test and length verification test.  We 
routinely use primers VF2 and VR for sequence verification of parts assembled in 
BioBrick vectors (Table I). 
5. Preparation of linearized destination vector by PCR to improve 3A assembly 
Our driving goal in designing the 3A assembly process was to limit the number of 
possible incorrect assembly products as much as possible by leveraging a combination of 
positive and negative selection (Figure 3).  Hence, incorrect clones arising from 3A 
assembly are of significant interest because they inform further improvements to the 
process.  In our experience, the three most common failure modes of 3A assembly are the 
following.  First, colonies on the transformation plate are resistant to the antibiotic 
corresponding to not only the destination vector but also one of the parent vectors.  Such 
a result generally arises from a co-transformation, or possibly a ligation followed by 
transformation, of the part and destination vectors.  Second, a contaminating E. coli 
genomic DNA fragment ligates to the destination vector backbone and is transformed.  In 
this error case, the genomic DNA fragment is often flanked by EcoRI and PstI sites and 
can ligate directly to the destination vector.  Such a two-fragment ligation event competes 
with the desired three-fragment ligation event needed for correct part assembly.  Third, 
uncut or recircularized destination vector propagates in the host strain as a result of a 
loss-of-function mutation in the ccdB positive selection marker.   
 
While the verification tests described above can generally detect these three error cases 
prior to DNA sequencing, we prefer to reduce or eliminate these failure cases if possible.  
In particular, both the second and third failure modes described above stem from issues 
arising during preparation and digestion of the destination vector.  To further reduce the 
number of possible incorrect assembly products in 3A assembly, we recommend 
preparing the destination vector by PCR instead of by plasmid DNA purification.  Such 
an approach nearly eliminates contaminating genomic DNA in the destination vector 
digestion reaction, thereby reducing competition from EcoRI/PstI linearized genomic 
DNA fragments in the ligation reaction (second failure mode).  Similarly, preparation of 
the destination vector by PCR also reduces contaminating uncut destination plasmid from 
the transformation reaction (third failure mode).  Since destination vectors can be 
prepared in batches in advance of any assembly steps, the duration and automation of the 
3A assembly process is unaffected by these improvements. 
 
1. Amplify the pSB1A3, pSB1K3, pSB1C3 and pSB1T3 destination vectors by PCR 
using primers SB-prep-3P and SB-prep-2Eb (Table I).  Prepare each amplification 
reaction with 1X PCR SuperMix High Fidelity (Life Technologies, Carlsbad, 
CA), 60 pmol each primer and 2-5 ng template destination plasmid in a 100 µL 
total volume.  We designed the primers to amplify the destination vector with 
only EcoRI and PstI recognition sites, leaving only the minimal number of bases 
5’ to the sites to allow efficient DNA cleavage of the vector by these enzymes.  
The resulting short fragments produced from digestion of the PCR-amplified 
destination vector are too short for ligation during assembly, increasing the 
efficiency of the assembly step by limiting competing ligation products. 
2. Thermocycle the reactions using the following conditions. 
1. Initial denaturation at 94°C for 1 minute. 
2. Denaturation step at 94°C for 30 seconds. 
3. Annealing step at 58°C for 30 seconds. 
4. Extension step at 68°C for 3 minutes. 
5. Cycle 40 times to step 2. 
6. Final extension at 68°C for 10 minutes. 
3. Add 1 ul DpnI to each reaction. 
4. Incubate all reactions at 37°C for 1 hour to digest the template DNA and then at 
80°C for 20 minutes to heat inactivate the restriction enzyme.  For convenience, 
we recommend performing this step in a programmable thermocycler. 
5. Confirm by agarose gel electrophoresis that the full-length destination vector is 
primary PCR product. 
6. Purify the PCR product using the QIAquick PCR Purification Kit from QIAGEN 
or similar kit to remove enzymes and dNTPs. 
7. The resulting PCR-amplified destination vector can be used directly in the EcoRI 
and PstI digestion of a 3A assembly step.  We do not recommend storage of 
digested linearized plasmid backbones. 
6. Available BioBrick destination vectors 
Several standard BioBrick assembly vectors are available from the Registry of Standard 
Biological parts including high copy vectors pSB1A3, pSB1K3, pSB1C3, pSB1T3, 
pSB1AK3, pSB1AC3 and pSB1AT3. In addition, a selection of low and medium copy 
BioBrick vectors are also available from the Registry including pSB4A5, pSB4K5, 
pSB4C5, pSB4T5, pSB3K5, pSB3C5 and pSB3T5 (Shetty et al., 2008). All of these 
vectors contain a BioBrick cloning site and primer binding sites for verification primers 
VF2 and VR.  The VF2 and VR primer binding sites are positioned at a sufficient 
distance from the cloning site to allow high quality sequence reads of BioBrick parts 
from Sanger sequencing.  Use of part plasmids and destination plasmids with different 
replication origins can increase the likelihood that ligation products containing two 
replication origins will propagate during cell growth (first failure mode described above).   
7. Preparation of chemically competent cells 
A key factor in the success of 3A assembly of BioBrick parts is the transformation 
efficiency of the competent cells used.  Low efficiency competent cells can result in few 
or no colonies on the transformation plate.  We have tested several different protocols for 
preparation of chemically competent cells and have found that the following protocol 
yields competent cells with high transformation efficiency.  It builds on extensive prior 
work on bacterial transformation (Hanahan et al., 1991).  We have used this protocol 
successfully with E. coli strains TOP10 and Mach1. 
 
1. Detergent residue inhibits competent cell growth and transformation. Remove 
detergents from all glassware by autoclaving glassware filled ! full with DI water 
prior to use.  Prepare all media and buffers in detergent-free glassware.  Similarly, 
grow cultures in detergent-free glassware. 
2. Prepare CCMB80 buffer. 
• 10 mM KOAc pH 7.0 (10 mL of a 1M stock solution) 
• 80 mM CaCl2!2H2O (11.8 g/L) 
• 20 mM MnCl2!4H2O (4.0 g/L) 
• 10 mM MgCl2!6H2O (2.0 g/L) 
• 10% glycerol 
• Adjust pH down to 6.4 with 0.1N HCl if necessary. 
• Filter sterilize and store at 4°C. 
3. Streak the E. coli strain on an SOB agar plate and grow at 23°C until single 
colonies appear. 
4. Prepare a set of seed cultures by picking single colonies into several culture tubes 
each with 2 mL SOB medium.  Shake culture tubes at 23°C overnight. 
5. Prepare frozen seed stocks by adding sterile glycerol to a final concentration of 
15% to each seed culture.  Aliquot 1 mL seed culture into cryogenic vials.  Freeze 
seed stocks in a dry ice/ethanol bath and store at -80°C. 
6. Inoculate 250 mL SOB medium with a 1 mL vial of seed stock and grow at 20°C 
to an OD600nm of 0.3.  This culture may be grown at room temperature if 
necessary. 
7. Chill glassware, plasticware and reagents prior to use. 
8. Centrifuge the culture at 3000 x g at 4°C for 10 minutes in a flat bottom 
centrifuge tube.  The cell pellet is easier to resuspend in a flat bottom tube. 
9. Gently resuspend cell pellet in 80 mL of ice cold CCMB80 buffer.  To make cell 
resuspension easier, initially add a small volume of buffer, resuspend and then 
add the rest of the buffer. 
10. Incubate resuspended culture on ice for 20 minutes. 
11. Centrifuge resuspended culture at 3000 x g at 4°C for 10 minutes and gently 
resuspend cell pellet in 10 mL ice cold CCMB80 buffer. 
12. Measure the OD600nm of a mixture of 200 µL SOC and 50 µL resuspended 
culture.  Add sufficient chilled CCMB80 buffer to resuspended culture to yield a 
final OD600nm of 1.0-1.5 in this measurement. 
13. Incubate the resuspended culture on ice for 20 minutes. 
14. Aliquot competent cells into pre-chilled tubes and store at -80°C. 
15. Measure transformation efficiency of prepared competent cells using plasmid 
DNA.  Target transformation efficiency is >108 cfu per µg of plasmid DNA. 
8. Conclusions 
3A assembly is a method for the assembly of standard biological parts that conform to 
BioBrick assembly standard 10.  The 3A assembly method relies on a combination of 
positive and negative selection to achieve a high frequency of correctly assembled clones 
(>80% in our experience).  It avoids labor-intensive, difficult-to-automate steps such as 
column cleanup and agarose gel purification and we have used it successfully with parts 
ranging in length from 12 bp to 3-4 kb.  To use 3A assembly, the destination vector, into 
which two BioBrick parts will be assembled, must have a different antibiotic resistance 
marker from the plasmids encoding the two input parts.  The 3A assembly method is 
extensible to other BioBrick assembly standards, assuming that the restriction enzymes 
used can be heat inactivated. 
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Table I: Primer sequences using during construction and 3A assembly of BioBrick parts  
 
Primer description (Name) Primer sequence 
Forward amplification primer for protein coding 
sequence parts 
5’ GTTTCTTCGAATTCGCGGCCGCTTCTAG [ATG + 15-21nt coding sequence] 3’ 
Forward amplification primer for all other parts 5’ GTTTCTTCGAATTCGCGGCCGCTTCTAGAG [18-24nt part sequence] 3’ 
Reverse amplification primer  5’ GTTTCTTCCTGCAGCGGCCGCTACTAGTA [18-24nt part sequence (reverse 
complement)] 3’ 
Forward colony verification primer (BioBricks-f) 5’ GTTTCTTCGAATTCGCGGCCGCTTCTAG 3’ 
Reverse colony verification primer (BioBricks-r) 5’ GTTTCTTCCTGCAGCGGCCGCTACTAGTA 3’ 
Forward sequencing primer (VF2) 5’ TGCCACCTGACGTCTAAGAA 3’ 
Reverse sequencing primer (VR) 5’ ATTACCGCCTTTGAGTGAGC 3’ 
Vector amplification primer (SB-prep-3P) 5’ GCCGCTGCAGTCCGGCAAAAAAACG 3’ 
Vector amplification primer (SB-prep-2Eb) 5’ ATGAATTCCAGAAATCATCCTTAGCGAA 3’ 
 
Table II: Restriction enzymes whose sites are recommended for removal when constructing BioBrick parts by de novo DNA synthesis 
 
Restriction enzyme Explanation 
EcoRI, XbaI, SpeI, PstI Required by BioBrick assembly standard 10 
NheI, PsrI, PpiI, AscI, PacI, MabI, BglII, BamHI, XhoI, 
NgoMIV, AgeI, AarI, XmaI, BspEI, BpuEI, BseRI, HindIII 
Compatibility with BioBrick assembly standards 12, 15, 
21, 25, 28, 37, 44 and 45 
ApoI, MfeI, AvrII, NsiI, SbfI Produce compatible cohesive ends to BioBrick assembly 
standard 10 enzymes 
BbsI, BbvI, BfuAI, BsmAI, BsmBI, BsmFI, BsaI, BspMI, 
BtgZI, EarI, FokI, HgaI, SapI, SfaNI 
Offset cutters that produce arbitrary 3-4 nt overhangs 
Nt.BsmAI, Nt.BspQI, Nt.BstNBI, Nt.AlwI Offset nicking enzymes 
 
Figure 1 
(A) Parts conforming to BioBrick assembly standard 10 are flanked on the 5’ end by a 
prefix sequence encoding EcoRI, NotI and XbaI restriction enzyme recognition sites and 
on the 3’ end by a suffix sequence encoding SpeI, NotI, and PstI recognition sites.  (B) 
BioBrick parts encoding protein coding sequences generally begin with an ATG start 
codon and end with two TAA stop codons.  The prefix sequence is truncated by 2 bp on 
the 3’ end relative to other types of BioBrick parts.  The truncation ensures that, when 
assembled, the Shine-Dalgarno sequence of a ribosome binding site part and the ATG 
start codon of a protein coding sequence part have correct, intervening spacing for 
expression in E. coli and related hosts.  (C) Assembly of two BioBrick parts results in a 
new BioBrick part with appropriate prefix and suffix sequences.  An 8 bp “mixed” or 
“scar” sequence is formed between the upstream and downstream parts that is not 
recognized by any of the BioBrick enzymes.  Thus, the composite BioBrick part can be 
reused in another assembly step. 
        EcoRI          NotI              XbaI                                                   SpeI              NotI          PstI
5' GAATTC GCGGCCGC T TCTAGA G [part sequence] T ACTAGT A GCGGCCG CTGCAG 3'
3' CTTAAG CGCCGGCG A AGATCT C [part sequence] A TGATCA T CGCCGGC GACGTC 5'
    BioBrick assembly standard 10 prefix                                 BioBrick assembly standard 10 suffix
        EcoRI          NotI              XbaI                                                   SpeI              NotI          PstI
5' GAATTC GCGGCCGC T TCTAG    [ATG....TAATAA] T ACTAGT A GCGGCCG CTGCAG 3'
3' CTTAAG CGCCGGCG A AGATC    [TAC....ATTATT] A TGATCA T CGCCGGC GACGTC 5'
   
BioBrick assembly standard 10 CDS prefix                             BioBrick assembly standard 10 suffix
        EcoRI          NotI              XbaI                                                 mixed                                                      SpeI              NotI          PstI
5' GAATTC GCGGCCGC T TCTAGA G [upstream part] T ACTAGA G [downstream part] T ACTAGT A GCGGCCG CTGCAG 3'
3' CTTAAG CGCCGGCG A AGATCT C [upstream part] A TGATCT C [downstream part] A TGATCA T CGCCGGC GACGTC 5'
    BioBrick assembly standard 10 prefix                                                                                               BioBrick assembly standard 10 suffix
A
B
C
Figure 2 
Schematic overview of the 3A assembly process for assembly of BioBrick parts. The 
destination plasmid must have a different antibiotic resistance marker from both the 
upstream and downstream part plasmids.  To perform a 3A assembly, digest the upstream 
part plasmid with EcoRI and SpeI.  Digest the downstream part plasmid with XbaI and 
PstI.  Digest the destination plasmid with EcoRI and PstI.  Ligate the resulting DNA 
fragments to form a circular plasmid composed of the destination vector and composite 
part and then transform.  Abbreviations are as follows: E=EcoRI site, X=XbaI site, 
S=SpeI site, P=PstI site, M=mixed XbaI/SpeI site, 1=pUC19-derived high copy 
replication origin, A=ampicillin resistance marker, K=kanamycin resistance marker, 
C=chloramphenicol resistance marker, R0010=BBa_R0010, I13507=BBa_I13507 and 
P1010=BBa_P1010.  BBa_R0010 is a BioBrick genetic part encoding a LacI-repressible 
promoter.  BBa_I13507 is a composite BioBrick genetic part composed of a ribosome 
binding site, monomeric red fluorescent protein coding sequence and a transcriptional 
terminator.  BBa_P1010 encodes the ccdB positive selection marker. 
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Figure 3 
An overview of selective pressures for or against possible ligation products from the 3A 
assembly process.  (A) The desired ligation product is composed of a composite part in 
the destination vector.  (B) Colony growth usually selects against ligation products with 
two or more identical replication origins.  Alternatively, transformed colonies can be 
screened for resistance to only the antibiotic corresponding to the destination vector.  (C) 
Part concatemers are possible but occur with significantly lower frequency than the 
desired ligation product.  (D) Expression of ccdB positive selection marker is toxic to 
growth of E. coli cloning strains preventing propagation of uncut or recircularized 
destination plasmid.  (E) Transformation and subsequent growth selects against both 
linear ligation products and circular ligation products without a replication origin.  (F) 
Growth on selective media selects for presence of destination vector in the ligation 
product.  There is no selection for propagation of the part plasmid.  Abbreviations are 
identical to Figure 2. 
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